HTB

Published ahead of print

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load

Long-acting ART for children is a deferred priority despite achievable dosing

Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold

Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high

Reducing rates of HIV-related cancer in US from 1996-2012

Dolutegravir use in pregnancy: results from small Belgian cohort

Reassuring French data using raltegravir during pregnancy

16th European AIDS Conference (EACS 2017)

D/C/F/TAF: no impact on bioavailability of when tablet split but TAF reduced when crushed

Dolutegravir linked to less sleep but not cardiovascular or other CNS side effects, or IRIS

Dolutegravir-based dual therapy as switch option in multiple studies

D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets

ABX464 nudges viral reservoir but not time to viral rebound

Effects of the anti-inflammatory antibody canakinumab on heart disease and cancer: implications for HIV?

Estimating the total size of the HIV reservoir

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results

Updated European guidelines launched at EACS 2017